Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study.
Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study.
复制标题
DOI：
10.1016/j.cmi.2021.01.005
复制
发表时间：
2021-01-20
期刊：
影响因子：
--
通讯作者：
Geneva Centre for Emerging Viral Diseases
中科院分区：
文献类型：
--
作者：
L'Huillier AG;Meyer B;Andrey DO;Arm-Vernez I;Baggio S;Didierlaurent A;Eberhardt CS;Eckerle I;Grasset-Salomon C;Huttner A;Posfay-Barbe KM;Royo IS;Pralong JA;Vuilleumier N;Yerly S;Siegrist CA;Kaiser L;Geneva Centre for Emerging Viral Diseases
纵向评估2019年轻度冠状病毒病（COVID-19）医院员工队列中长达6个月的体液免疫持续性。我们在200名医院工作人员中使用商业ELISA和替代病毒中和试验，在大多数轻度COVID-19后的1个月，3个月和6个月测量了抗RBD（病毒刺突蛋白的受体结合结构域），抗N（病毒核蛋白）和中和抗体。严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性抗体在所有参与者中持续长达6个月。在整个队列中，抗RBD几何平均浓度（GMC）在第1个月（74.2 U/mL，95%CI：62.7-87.8）、第3个月（103.2 U/mL，95%CI：87.9-121.2; p < 0.001）和第6个月（123.3 U/mL，95%CI：103.4-147.0; p < 0.001）之间逐渐增加。抗-N抗体在所有时间>97%中可检测。感染后6个月，99.5%的参与者（195/196）可检测到中和抗体。他们的GMC在第1个月（20.1 Au/mL，95%CI：16.9-24.0）、第3个月（15.2 Au/mL，95%CI：13.2-17.6; p < 0.001）和第6个月（9.4 Au/mL，95%CI：7.7-11.4; p < 0.001）之间进行性降低。在每个时间点，RBD-ACE 2抑制抗体滴度和抗RBD抗体浓度强烈相关（所有r > 0.86，p < 0.001）。疾病严重程度与较高的初始抗RBD和RBD-ACE 2抑制抗体滴度相关，但与其动力学无关。中和抗体在几乎所有参与者中持续了6个月，表明比最初担心的更持久。抗RBD抗体持续更好，甚至随着时间的推移而增加，可能与优先检测亲和力逐渐升高的抗体有关。
To evaluate longitudinally the persistence of humoral immunity for up to 6 months in a cohort of hospital employees with mild coronavirus disease 2019 (COVID-19). We measured anti-RBD (receptor binding domain of viral spike protein), anti-N (viral nucleoprotein) and neutralizing antibodies at 1, 3 and 6 months after mostly mild COVID-19 in 200 hospital workers using commercial ELISAs and a surrogate virus neutralization assay. Antibodies specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) persisted in all participants for up to 6 months. Anti-RBD geometric mean concentrations (GMCs) progressively increased between months 1 (74.2 U/mL, 95%CI: 62.7–87.8), 3 (103.2 U/mL, 95%CI: 87.9–121.2; p < 0.001), and 6 (123.3 U/mL, 95%CI: 103.4–147.0; p < 0.001) in the whole cohort. Anti-N antibodies were detectable in >97% at all times. Neutralizing antibodies were detectable in 99.5% of participants (195/196) at 6 months post infection. Their GMC progressively decreased between months 1 (20.1 AU/mL, 95%CI: 16.9–24.0), 3 (15.2 AU/mL, 95%CI: 13.2–17.6; p < 0.001) and 6 (9.4 AU/mL, 95%CI: 7.7–11.4; p < 0.001). RBD-ACE2-inhibiting antibody titres and anti-RBD antibody concentrations strongly correlated at each timepoint (all r > 0.86, p < 0.001). Disease severity was associated with higher initial anti-RBD and RBD-ACE2-inhibiting antibody titres, but not with their kinetics. Neutralizing antibodies persisted at 6 months in almost all participants, indicating more durability than initially feared. Anti-RBD antibodies persisted better and even increased over time, possibly related to the preferential detection of progressively higher-affinity antibodies.
登录
查看更多内容
影响因子：
82.9
作者：
Long, Quan-Xin;Liu, Bai-Zhong;Huang, Ai-Long
通讯作者：
Huang, Ai-Long
影响因子：
158.5
作者：
Gudbjartsson, Daniel F.;Norddahl, Gudmundur L.;Stefansson, Kari
通讯作者：
Stefansson, Kari
影响因子：
46.9
作者：
Tan, Chee Wah;Chia, Wan Ni;Wang, Lin-Fa
通讯作者：
Wang, Lin-Fa
SARS-CoV-2 感染引起的人类中和抗体
影响因子：
64.8
作者：
Ju, Bin;Zhang, Qi;Zhang, Linqi
通讯作者：
Zhang, Linqi
影响因子：
11.1
作者：
Fafi-Kremer S;Bruel T;Madec Y;Grant R;Tondeur L;Grzelak L;Staropoli I;Anna F;Souque P;Fernandes-Pellerin S;Jolly N;Renaudat C;Ungeheuer MN;Schmidt-Mutter C;Collongues N;Bolle A;Velay A;Lefebvre N;Mielcarek M;Meyer N;Rey D;Charneau P;Hoen B;De Seze J;Schwartz O;Fontanet A
通讯作者：
Fontanet A